This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Amag-Allos: Worst Bio-Merger in History

Stocks in this article: ALTHAMAG

Updated with more deal information.

LEXINGTON, Mass. ( TheStreet) -- Amag Pharmaceuticals (AMAG) is merging with Allos Therapeutics (ALTH) in what might be the nuttiest, most nonsensical business combination in biotech history.

The only thing Amag and Allos have in common is that they've largely failed initial efforts to sell their respective drugs, neither of which have anything to do with each other.

Amag's commercial launch of Feraheme, an injectable iron replacement therapy for anemia in patients with chronic kidney disease, has been a major disappointment. The same can be said for Allos' lymphoma cancer drug Folotyn.

Ideally, mergers bring together two companies that can capitalize on their respective strengths to make the sum better, stronger, more capable than the individual parts. Wednesday's merger of Amag and Allos does no such thing. It's just two disparate and under-performing biotech companies getting hitched to, at best, save some money.

"We are very excited about this merger as it creates a combined company with an enhanced commercial presence in attractive market segments supported by a more efficient organizational structure," said Brian Pereira, CEO of Amag in a statement that fails on so many levels to rationalize this deal.

Pereira, by the way, will retain the CEO title in the as-yet-unnamed combined company.

Under terms of the deal, Allos shareholders will receive a fixed ratio of 0.128 shares of Amag common stock for each share of Allos common stock they own. At Amag's Tuesday closing price of $19.07, the deal values Allos at $2.44 a share, or $260 million total.

Allos shares closed Tuesday at $2.06 a share.

Allos received U.S. approval for Folotyn in September 2009. At that time, Allos shares traded for around $8 a share. That was basically the high point for Allos's stock price.

Amag's Feraheme was approved in the U.S. in July 2009 when Amag shares traded around $56 a share. Like Allos, Amag' stock price never saw brighter days. The stock fell steadily as Feraheme sales lagged expectations.

The merger of Amag and Allos: Not exactly a match made in heaven.

--Written by Adam Feuerstein in Boston.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,118.13 +143.82 0.85%
S&P 500 0.00 -2.75 -0.14%
NASDAQ 4,536.4810 -12.7450 -0.28%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs